Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Phase II Trial
100%
Nonalcoholic Steatohepatitis
100%
Randomized Placebo-controlled Trial
100%
Interim Analysis
100%
Fibrosis
43%
Placebo Groups
31%
Fibrosis Stage
18%
One Dose
12%
Cirrhosis
12%
Chronic Liver Disease
12%
Moderate to Severe
6%
Comorbidity
6%
Response System
6%
Safety Profile
6%
Biochemical Markers
6%
Disease Activity
6%
Confounding
6%
Clinical Outcomes
6%
Placebo
6%
Treatment Group
6%
Adverse Events
6%
Phase II Study
6%
Clinically Significant
6%
Clinical Benefit
6%
Alcohol Consumption
6%
Adult Patients
6%
Serious Adverse Events
6%
Histopathological Features
6%
Pruritus
6%
Farnesoid X Receptor
6%
1-stage
6%
Overall Safety
6%
Histological Markers
6%
Randomized Double-blind Placebo-controlled Study
6%
Intention-to-treat
6%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Nonalcoholic Fatty Liver
100%
Fibrosis
62%
Adverse Event
12%
Liver Cirrhosis
12%
Chronic Liver Disease
12%
Drug
6%
Receptor Agonist
6%
Ethanol
6%
Placebo-Controlled Study
6%
Disease Activity
6%
Pruritus
6%
Farnesoid X Receptor
6%
Biochemical Marker
6%
Comorbidity
6%
Treatment Group
6%